Safrazine

Safrazine
Clinical data
Other names	4-benzo[1,3]dioxol-5-ylbutan-2-ylhydrazine; [3-(3,4-(methylenedioxy)phenyl)-1-butyl]hydrazine; 2-piperonylisopropylhydrazine
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name [3-(1,3-benzodioxol-5-yl)-1-methyl-propyl]hydrazine;
CAS Number	33419-68-0;
PubChem CID	34042;
ChemSpider	31375;
UNII	F5G0P5378C;
CompTox Dashboard (EPA)	DTXSID60860006 ;
Chemical and physical data
Formula	C11H16N2O2
Molar mass	208.261 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(CCc2ccc1OCOc1c2)NN;

Safrazine (Safra) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was introduced as an antidepressant in the 1960s, but has since been discontinued alongside several old generation MAOIs in favor of the invention of RIMAs and more efficacious treatments for depression in general. ^[1]

References

^ Morton I, Morton IK, Hall JM (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 251–. ISBN 978-0-7514-0499-9.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[MortonMorton1999-1] Morton I, Morton IK, Hall JM (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 251–. ISBN 978-0-7514-0499-9.

[1]

See also

References